{
    "Trade/Device Name(s)": [
        "SAFECARE Fentanyl Urine Test Cassette",
        "SAFECARE FYL Urine Test Cassette"
    ],
    "Submitter Information": "Safecare Biotech (Hangzhou) Co. Ltd.",
    "510(k) Number": "K240654",
    "Predicate Device Reference 510(k) Number(s)": [
        "K233417"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NGL"
    ],
    "Summary Letter Date": "March 2, 2024",
    "Summary Letter Received Date": "March 7, 2024",
    "Submission Date": "April 8, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Competitive binding",
        "Lateral flow immunochromatographic assay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Cassette"
    ],
    "Document Summary": "FDA 510(k) summary for SAFECARE Fentanyl Urine Test Cassette for qualitative detection of fentanyl in human urine via competitive binding lateral flow immunochromatographic assay",
    "Indications for Use Summary": "For qualitative detection of fentanyl in human urine at 1 ng/mL cutoff, intended for over-the-counter and in vitro diagnostic use; preliminary results require confirmation by GC/MS or LC/MS",
    "fda_folder": "Toxicology"
}